Diary - News All news Orphelia Pharma : CHMP has adopted a positive opinion for Ivozall

Orphelia Pharma : CHMP has adopted a positive opinion for Ivozall

ORPHELIA Pharma announces that the CHMP has adopted a positive opinion for Ivozall® (clofarabine 1 mg/ml), an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

Paris and Lyon, October 1^st, 2019 – ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of paediatric drugs in the fields of oncology and neurology, announces today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the issuance of a marketing authorization for Ivozall®.

Read the press release

Headlines

Our members

Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens

April 12^th, 2021

DEINOVE benefits from the support of the French government, within the framework of the “France Relance” plan, to accelerate the development of new antimicrobials

March 11^th, 2021

DEINOVE has been selected as part of the “France Relance” plan

March 23^th, 2021

All news